Monitoring of the concentration of gentamicin in serum and plasma during therapy is widely recommended and practiced in hospitals. Our aim was to develop a homogeneous immunoassay based on particle-enhanced turbidimetric inhibition immunoassay technology to quantify gentamicin on the Dimension ® clinical chemistry system. Methods: Assay performance was assessed on each of the Dimension models in a 15-instrument interlaboratory comparison study. A split-sample comparison (n ‫؍‬ 1171) was also performed between the gentamicin methods on the Dimension system and the Abbott ® TDx ® analyzer, using multiple reagent and calibrator lots on multiple instruments. Results: The Dimension method was linear to 25.1 mol/L (12.0 g/mL) with a detection limit of 0.63 mol/L (0.3 g/mL). Calibration was stable for 30 days. The within-run imprecision (CV) was <1.3%, and total imprecision ranged from 1.8% to 3.2% between 4.2 mol/L (2.0 g/mL) and 16.7 mol/L (8.0 g/mL) gentamicin. Linear regression analysis of the results on the Dimension method (DM) vs the Abbott TDx yielded the following equation: DM ‫؍‬ 0.98TDx ؊ 0.42; r ‫؍‬ 0.987. Minimal interference was observed from structurally related compounds such as sagamicin, netilmicin, and sisomicin. Conclusion: The monoclonal antibody used in this method has similar reactivities toward the individual gentamicin subspecies C1, C1a, and C2, thus providing analytical recovery not significantly dependent on relative subspecies concentrations.
Because excess accumulation of gentamicin in blood can lead to renal tubular necrosis and degeneration of the auditory nerve (1 ) monitoring the concentration of this drug during therapy is widely recommended and practiced in hospitals (2, 3 ) . Clinical laboratory trends toward workstation consolidation are apparent, and this has increased the importance of performing therapeutic drug monitoring (TDM) 1 assays on high-throughput, multipurpose clinical chemistry analyzers. A particle-enhanced turbidimetric inhibition immunoassay (PETINIA) was thus developed for the measurement of gentamicin on the Dimension ® clinical chemistry system. 2 Features and performance of this assay are discussed here.
In the assay, gentamicin linked to latex particles reacts with a F(abЈ) 2 fragment of an anti-gentamicin monoclonal antibody to form aggregates that increase the turbidity of the solution. Free gentamicin from the sample competes for the antibody fragment, thereby decreasing the rate of particle aggregation. Thus, the rate of aggregation is inversely proportional to the concentration of gentamicin in the sample. The rate of turbidity increase is measured bichromatically at 340 and 700 nm and converted to analyte concentration using a logit transformation (4 ) . The particles are 65 Ϯ 10 nm in diameter and composed of a polystyrene core and a polyglycidylmethacrylate shell. The particles were prepared according to procedures described previously (5 ) .
The assay was designed for robustness relative to several performance attributes. This included relative Drug Monitoring and Toxicology consistency of analytical recovery for the C1, C1a, and C2 subspecies (6 ) in pharmaceutical gentamicin preparations. Thus, we used a monoclonal antibody that reacts similarly with all of these subspecies. F(abЈ) 2 fragments were used as a precaution to prevent nonspecific binding, which can occur when rheumatoid factor binds to Fc fragments of intact antibodies (7) (8) (9) (10) . As an additional precaution, operating parameters were included to prevent the reporting of results from the very rare presence of nonspecific aggregation that can arise from unusual serum constituents. Because the Dimension system encompasses a family of instrument models, assay performance was assessed on each of these in a 15-instrument interlaboratory comparison study.
Although the main purpose here is to describe assay features and analytical performance, we also describe results of work done to shed light on the mechanism of the agglutination reaction used. Craig (11 ) proposed previously that the immunospecific binding of antibody fragments to analyte-modified particles changes the colloidal properties of the latex particles, thus triggering agglutination without the need for bridging of particles by the bivalent antibody. Strong evidence for the validity of this mechanism was reported by Thompson et al. (12 ) in a detailed study of the kinetics and mechanism of reactions involved in a PETINIA test for phenytoin. Data on the gentamicin assay described here suggest a similar mechanism.
Materials and Methods
Gentamicin Flex TM reagent cartridges were from Dade Behring Inc. These contained particle reagent, antibody reagent, and buffer. The antibody reagent is a F(abЈ) 2 fragment prepared by standard procedures (13 ) . The parent monoclonal antibody was derived from a hybridoma cell line resulting from fusion of spleen cells of BALB/c mice immunized with gentamicin-bovine serum albumin and mouse myeloma cells, using standard techniques (14 ) . The particle reagent is described above. Specimens (serum, plasma) were from several hospitals. DADE ® IMMUNOASSAY (COMPREHENSIVE TRI-LEV-EL), DADE TDM, BIORAD ® LIQUICHEK TM TDM and LYPHOCHEK TM TDM, CIBA-CORNING TDM, HYCOR SENTRY ® COMBO-TROL controls were used. For recovery and linearity studies, U.S. Pharmacopeia (USP) gentamicin sulfate was dried under reduced pressure not exceeding 5 mmHg at 110°C for 3 h and added immediately to gentamicin-free serum pools to give the reported concentrations. For stability studies, Beckman Gentamicin Calibrator containing gentamicin concentrations of 0.0, 2.1, 4.2, 8.4, 16.7, and 25.1 mol/L (0.0, 1.0, 2.0, 4.0, 8.0, and 12 g/mL) was used. Calibration was performed with Dimension system Drug Calibrator II (Dade Behring Inc.), a multianalyte calibrator that includes gentamicin concentrations of approximately 0.0, 3.1, 6.0, 12.5, and 25.1 mol/L (0.0, 1.5, 3.0, 6.0, and 12.0 g/mL). The calibrator bottle values are assigned by a master pool anchored to USP gentamicin sulfate (lot J) using two Dimension instruments. Gentamicin subspecies C1, C1a, and C2 were purified using HPLC (Waters Model 510) and a DuPont Absorbance was measured continuously (nonroutine mode of instrument operation) on a Dimension system model AR at 340 and 700 nm wavelengths. R1, R2, and R3 indicate the times at which the instrument measures these absorbances during routine assay processing. The lines show the measured difference in the two absorbances over time for 0.0 and 25.1 mol/L (12 g/mL) gentamicin calibrators. In the routine operating mode, particle reagent (PR) and buffer are first added to the cuvette, followed by water, and mixed ultrasonically. Sample (3 L) is added, followed by water, and the contents mixed ultrasonically. R1 and R2 measurements are performed to detect any unusual nonspecific agglutination that might occur and which would be flagged as errors. Antibody reagent is then added, and a final measurement (R3) is made at a fixed time. The measured bichromatic R2 absorbance is subtracted from that for R3, the difference being inversely proportional to the concentration of gentamicin in the sample.
Fig. 2. Representative gentamicin calibration curve.
Data were obtained on a Dimension system, model AR. Points show means of duplicate determinations for calibrators with five concentrations of gentamicin. The logit curve fit was used to obtain calibration coefficients for the slope, intercept, C2, and C3 with a fixed C4 term (0.5). ZORBAX ® Sil column (21.2 ϫ 25 cm) as described by Anhalt et al. (15 ) . The mobile phase used was H 2 O: methanol:diethylamine (60:40:0.5, by volume). After 1.0 mL of gentamicin sulfate (Sigma Chemical Co.; lot no. 42H06105) was injected, the subspecies were separated in the column by an isocratic running program at a flow of 5.0 mL/min. A split-sample correlation study was performed in our laboratories and two clinical hospital laboratories. Serum specimens used in our laboratories were acquired from several hospital laboratories, shipped on dry ice, and subsequently stored frozen at Ϫ20°C until thawed before use. Clinical specimens used in hospital laboratories were treated the same way. Analyses were performed on both the Dimension system and TDx ® analyzer on the same day, once a sample was thawed.
More than 6000 samples were screened for human anti-mouse antibodies, using murine monoclonal antibodies with different specificity in sandwich assays as proposed by Vaidya and Beatty (16 ) . Nine positive samples from the screening test were selected randomly for the interference testing in this study. Also used was a serum sample that showed the most severe murine heterophilic antibody interference among all the positive samples we collected. The interlaboratory comparison was done with a full-factorial design, in which individual instruments and days of the study were the experimental factors. Dade ® IAC TDM controls, three serum pools, and one lot of calibrator were run in five replicates per day over 5 consecutive days on each of 15 calibrated Dimension instruments, including the XL, AR, ES, and SMS models. The instruments were physically located in five separate laboratories. We used JMP ® statistical software (SAS Institute, Inc.) to analyze the data.
Processing of gentamicin assays on the Dimension system, as directed by the system software, is depicted and described briefly in Fig. 1 . Data shown were captured in a nonroutine processing mode, in which absorbances are monitored continuously. Operating principles of the Dimension system have been published previously (17 ) . Experiments to explore the response of the assay over a wide range of antibody concentrations were done as described earlier for another assay system (11 ) .
Results and Discussion
The clone used to produce the monoclonal antibody in this assay was selected from a number of hybridoma fusions based on several criteria important to analytical performance. Characteristics screened included ability to agglutinate gentamicin-modified latex particles, antibody specificity (minimum cross-reactivity with other aminoglycoside drugs), and similarity of reactivities of various gentamicin subspecies. (Gentamicin is a fermentation product containing a mixture of antibiotics including a Samples for gentamicin subspecies were prepared by adding the subspecies to drug-free human serum. The same samples were measured by the Dimension system and Abbott TDx analyzers and represent means of 10 and 3 replicate determinations, respectively. The study was aimed at relative (Dimension system vs TDx analyzer), not absolute, recovery of subspecies; therefore, although all subspecies were treated the same, they were neither dried extensively nor tested for any possible impurities from the HPLC mobile phase.
gentamicin, C1, C1a, and C2 subspecies.) Fig. 2 shows a typical calibration curve, which indicates agglutination more than sufficient for application in a clinical assay. The specificity characteristics of the assay are indicated in Table 1 , and the responses for gentamicin subspecies are presented in Table 2 along with data for the Abbott ® TDx analyzer. Results show similarity of the two assays in this respect.
In the course of our investigations, several patient specimens containing high rheumatoid factor titers interfered with the assay using the intact monoclonal antibody. F(abЈ) 2 fragments prepared by pepsin digestion showed no such interference; therefore, this step was incorporated into the manufacturing process for the antibody reagent. The particle reagent formulation was optimized by adjusting the concentration of gentamicin used in the conjugation to achieve various densities of analyte analog on the particle surface; the formulation was selected for precise analytical results across the range of the calibration curve. The curve shape and the overall range of absorbance changes for the optimized reagents are shown in Fig. 2 . An error routine was incorporated into the software, as described in the caption of Fig. 1 . If agglutination was to occur before antibody is added, indicating a sample substance interacting with particles, the assay result would be aborted. We did not observe such a case in these studies on this particular analyte.
Both within-run and total precision were excellent for serum and plasma determinations, as summarized in Table 3 . The data were obtained using a Dimension system (model AR) and are representative of the precision observed for all four instrument models used in this testing. Although precision on individual instruments provides important information about the assay, it does not indicate the total method variability such as might be observed in a multisite proficiency survey. We thus performed an interlaboratory comparison study as described above. The results are reported in Table 4 . The overall SD, which may be taken as a realistic predictor of the variability expected in College of American Pathologists (CAP) or other multianalyte surveys, indicate very good multilaboratory performance with one reagent and one calibrator lot.
The results of split-sample studies, shown in Fig. 3 for the subject assay in comparison with the Abbott TDx analyzer, show very good correlation. For maximum robustness of the comparisons investigated, we used multiple lots of reagents and multiple instruments and calibrators, as detailed in the caption of Fig. 3 . The entire study occurred over 5 months and entailed five or more calibrations for each instrument.
The Bland-Altman form of the difference plot (18, 19 ) is also provided in Fig. 4 to show the measure of agreement between the two methods. It is apparent that there is no obvious relationship between the differences and measured concentrations. The mean difference and the SE of the mean differences were calculated to be Ϫ0.57 and 0.023 mol/L, respectively. At the 95% confidence interval, this is a significant but relatively minor systematic bias of Ϫ0.61 to Ϫ0.52 mol/L (Ϫ0.29 to Ϫ0.25 g/mL).
A direct comparison of serum results with plasma results was done on drug-free specimens to which gentamicin sulfate had been added. This approach was used to demonstrate the equivalence of the two sample matrices because of the lack of availability of matched draws from patients being administered gentamicin. This study, which included the anticoagulants sodium EDTA, lithium heparin, and potassium oxalate, showed the equivalence of the two specimen types. The regression statistics obtained were as follows: sodium EDTA result, 1.00 ϫ serum result ϩ 0.04 (n ϭ 21); lithium heparin result, 1.00 ϫ serum result Ϫ 0.04 (n ϭ 22); and potassium oxalate result, 1.01 ϫ serum result ϩ 0.02 (n ϭ 20). Actual patient plasma specimens containing gentamicin, when compared using the Dimension system and the Abbott TDx analyzer, gave correlation slopes not statistically different from the correlations with serum specimens.
The accuracy of the method was further evaluated by recovery of added USP gentamicin standard (carefully dried) and by results for CAP survey samples. By the addition technique, we found 102%, 105%, and 107% recovery for 4.2, 8.4, and 16.7 mol/L (2.0, 4.0, and 8.0 g/mL) of gentamicin. CAP survey samples Z-11 to Z- 15 (1995) were tested on the Dimension system model AR; the results were within evaluation criteria for peer group means. For example, the means of five replicates of samples measured on the Dimension system model AR were 15.9, 9.6, 2.9, 14.2, and 12.3 mol/L (7.6, 4.6, 1.4, 6.8, and 5.9 g/mL); the means of these same samples in the CAP survey were 15.3, 8.8, 2.7, 13.6, and 12.1 mol/L (7.3, 4.2, 1.3, 6.5, and 5.8 g/mL), respectively, for all the methods from Ͼ3700 clinical laboratories.
The limit of detection was 0.63 mol/L (0.3 g/mL) when defined as the concentration corresponding to 2 SD above the 0.0 mol/L value (n ϭ 20). Linearity was assessed by fitting the data to a quadratic model and by a test of significance of the coefficient of the second-degree term (20 ) . Linearity was thus found to extend beyond 25.1 mol/L (12 g/mL; data not shown).
The stability of the reagents is important to the shelf life and calibration interval of the product. Reagent cartridges, calibrated and periodically measured over 90 days, showed a maximum rate of change of 5% over a 30-day period of testing for the four highest calibrator concentrations. The zero-concentration calibrator showed no drift outside the limit of detection [0.63 mol/L (0.3 g/mL)]. Based on this, a 30-day calibration interval was assigned. In continuing studies extending over 1 year using 30-day calibration intervals, the overall drifts for all calibrators were Ͻ5%; thus, a shelf life of at least 12 months was obtained for this method.
During the investigation of the assay chemistry reported here, we performed experiments that allow us to comment on the possible mechanism of the agglutination reaction. It is commonly believed that latex agglutination immunoassay reactions proceed through linking of particles by the two arms of the bivalent antibody, and this is The data represent 1171 duplicate determinations for 761 clinical specimens. Each set of duplicates was performed on one of five Dimension systems used in the total study (three in our laboratories and two in separate clinical hospital laboratories). Three Abbott TDx analyzers were used across the study. Three reagent lots and three calibrator lots were used for the Dimension system, and two calibrator lots and three reagent lots were used for TDx analyzers. Values for the line are as follows: r ϭ 0.987; n ϭ 1171; S y͉x ϭ 0.78; slope ϭ 0.98 Ϯ 0.005; intercept ϭ Ϫ0.42 Ϯ 0.039. certainly true for some assays. In such cases, one expects a bell-shaped curve for a plot of the rate of turbidity increase vs antibody concentration. This is so because high antibody concentrations would saturate all antigenic sites on particles, disallowing cross-linking. We tested this, as shown in Fig. 5 . Even at molar excesses of antibody to particle of 350-fold, no decrease in reaction rate was seen. Thus, the reaction shows behavior similar in this respect to that of a phenytoin PETINIA assay described recently (11 ) . In that study, several of the authors of this study proposed that bivalent bridging is, in fact, not necessary for particle agglutination and confirmed this by demonstrating strong immunospecific agglutination imparted by a (monovalent) F(ab) fragment. We proposed that a rapid, immunospecific initial reaction of antibody with antigenic sites on the particle triggers a second, rate-limiting step of agglutination because of decreased colloidal stability imparted by the presence of protein (IgG) on the particle surface. We believe that is the case here, as well. Clearly, such behavior requires careful selection of reaction conditions to avoid interferences from serum constituents that could upset colloidal stability. The practicality of finding such conditions is demonstrated by the excellent analytical performance reported here. The PETINIA technology has been adapted to six other therapeutic drugs on the Dimension system.
We believe the addition of the gentamicin assay enhances the utility of this system for highly accurate and precise monitoring of therapeutic drugs in laboratory settings where workstation consolidation is advantageous.
